HOLOGRAPHIC NEXT GENERATION GENOMIC DNA SEQUENCING
DEAD

Serial Number

90024830

Owner

Carl Raymond Amos

Filing Date

Jun 28, 2020

Add to watchlist:

No watchlists yet
View on USPTO

HOLOGRAPHIC NEXT GENERATION GENOMIC DNA SEQUENCING Trademark

Serial Number: 90024830

HOLOGRAPHIC NEXT GENERATION GENOMIC DNA SEQUENCING is a trademark filed by Carl Raymond Amos on June 28, 2020. The trademark is classified under Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Carl Raymond Amos (6 trademarks)

8710 W. Hillsborough Ave #413
Tampa, FL 33615

Entity Type: 01

Trademark Details

Filing Date

June 28, 2020

Registration Date

Not Registered

Goods & Services

DNA analysis services for scientific research purposes; DNA analysis services to determine paternity; DNA screening for scientific research purposes; Genetic mapping for scientific purposes; Genetic testing for scientific research purposes; Genetic testing of laboratory animals for research purposes; Genome amplification; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development of new technology for others in the field of genetics; Development of new technology for others in the field of genomics; Development of new technology for others in the field of holographic genome sequencing; Development of new technology for others in the field of holographic genome testing; Development of new technology for others in the field of gene splicing; Development of new technology for others in the field of holographic gene splicing; Development of new technology for others in the field of decoding genes; Development of new technology for others in the field of decoding genomes; Development of new technology for others in the field of decoding DNA; Development of new technology for others in the field of holographic genome decoding; Development of new technology for others in the field of holographic genomic decoding; Development of new technology for others in the field of genome decoding holography; Development of new technology for others in the field of genomic DNA sequencing; Development of new technology for others in the field of holographic genomic DNA sequencing; Development of new technology for others in the field of genomic DNA sequencing holography; Drug, alcohol and DNA screening for forensic research purposes; Providing information in the field of plant genetics research resources; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing scientific research information in the field of genetics; Providing scientific research information in the field of genomics; Providing scientific research information in the field of holographic genome sequencing; Providing scientific research information in the field of holographic genome testing; Providing scientific research information in the field of gene splicing; Providing scientific research information in the field of holographic gene splicing; Providing scientific research information in the field of decoding genes; Providing scientific research information in the field of decoding genomes; Providing scientific research information in the field of decoding DNA; Providing scientific research information in the field of holographic genome decoding; Providing scientific research information in the field of holographic genomic decoding; Providing scientific research information in the field of genome decoding holography; Providing scientific research information in the field of genomic DNA sequencing; Providing scientific research information in the field of holographic genomic DNA sequencing; Providing scientific research information in the field of genomic DNA sequencing holography; Scientific research consulting in the field of genetics; Scientific research consulting in the field of genomics; Scientific research consulting in the field of holographic genome sequencing; Scientific research consulting in the field of holographic genome testing; Scientific research consulting in the field of gene splicing; Scientific research consulting in the field of holographic gene splicing; Scientific research consulting in the field of decoding genes; Scientific research consulting in the field of decoding genomes; Scientific research consulting in the field of decoding DNA; Scientific research consulting in the field of holographic genome decoding; Scientific research consulting in the field of holographic genomic decoding; Scientific research consulting in the field of genome decoding holography; Scientific research consulting in the field of genomic DNA sequencing; Scientific research consulting in the field of holographic genomic DNA sequencing; Scientific research consulting in the field of genomic DNA sequencing holography; Scientific research in the field of genetics and genetic engineering; Scientific research in the field of genetics; Scientific research in the field of genomics; Scientific research in the field of holographic genome sequencing; Scientific research in the field of holographic genome testing; Scientific research in the field of gene splicing; Scientific research in the field of holographic gene splicing; Scientific research in the field of decoding genes; Scientific research in the field of decoding genomes; Scientific research in the field of decoding DNA; Scientific research in the field of holographic genome decoding; Scientific research in the field of holographic genomic decoding; Scientific research in the field of genome decoding holography; Scientific research in the field of genomic DNA sequencing; Scientific research in the field of holographic genomic DNA sequencing; Scientific research in the field of genomic DNA sequencing holography; Structural and functional analysis of genomes; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Aug 23, 2023 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Aug 23, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Aug 23, 2023 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 9, 2023 GNRN
NON-FINAL ACTION E-MAILED
May 9, 2023 GNRT
NON-FINAL ACTION WRITTEN
May 9, 2023 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 11, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 10, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 10, 2023 TROA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 8, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 7, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 7, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 8, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jan 8, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jan 8, 2023 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 6, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 6, 2022 CRFA
ASSIGNED TO LIE
Dec 6, 2022 ALIE
NOTICE OF REVIVAL - E-MAILED
Oct 18, 2022 NREV
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 17, 2022 TROA
PETITION TO REVIVE-GRANTED
Oct 17, 2022 PETG
TEAS PETITION TO REVIVE RECEIVED
Oct 17, 2022 PROA
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Aug 19, 2022 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Aug 18, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Aug 18, 2022 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 4, 2022 GNRN
NON-FINAL ACTION E-MAILED
Feb 4, 2022 GNRT
NON-FINAL ACTION WRITTEN
Feb 4, 2022 CNRT
NOTICE OF REVIVAL - E-MAILED
Jan 8, 2022 NREV
PETITION TO REVIVE-GRANTED
Jan 7, 2022 PETG
TEAS PETITION TO REVIVE RECEIVED
Jan 7, 2022 PROA
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Nov 8, 2021 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Nov 8, 2021 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 26, 2021 GNRN
NON-FINAL ACTION E-MAILED
Apr 26, 2021 GNRT
NON-FINAL ACTION WRITTEN
Apr 26, 2021 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 22, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 22, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 22, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 22, 2020 GNRN
NON-FINAL ACTION E-MAILED
Sep 22, 2020 GNRT
NON-FINAL ACTION WRITTEN
Sep 22, 2020 CNRT
ASSIGNED TO EXAMINER
Sep 16, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 24, 2020 NWOS
NEW APPLICATION ENTERED
Jul 1, 2020 NWAP